Investigators in this retrospective cohort study sought to determine long-term outcomes for patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to PARP inhibitors.

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...

In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

US FDA grants Priority Review for Pfizer’s Talzenna plus Xtandi to treat metastatic prostate cancer: New York Pfizer Inc. announced that t ...